What's Happening?
Between December 29, 2025, and November 1, 2026, South Africa has identified 47 confirmed cases of respiratory diphtheria and 11 asymptomatic carriers of toxigenic C. diphtheriae. The majority of these confirmed cases, 77% (36/47), were reported in the Western
Cape, followed by Limpopo with 11% (5/47) and Gauteng with 13% (6/47). Recent updates indicate three new laboratory-confirmed cases of toxigenic diphtheria and one new asymptomatic carrier in Gauteng. Public health responses have been initiated for all suspected and confirmed cases. Respiratory diphtheria is a vaccine-preventable illness caused by toxigenic C. diphtheriae, which can affect individuals of all ages. Clinical symptoms include sore throat, low-grade fever, an adherent grayish-white membrane in the nose, pharynx, tonsils, or larynx, and/or enlarged glands in the neck (bull neck). Toxin-mediated systemic signs such as myocarditis, polyneuropathy, and renal damage can also occur.
Why It's Important?
The increase in diphtheria cases in South Africa highlights the ongoing global challenge of vaccine-preventable diseases, even in the context of other public health concerns like COVID-19 surveillance. While the immediate impact is localized to South Africa, the interconnectedness of global health means that outbreaks in one region can pose risks to others, particularly with international travel. The emphasis on early administration of diphtheria anti-toxin (DAT) and prompt treatment underscores the severity of the disease and the importance of rapid medical intervention to prevent life-threatening complications. The situation also serves as a reminder of the critical role of vaccination programs in maintaining herd immunity and preventing the resurgence of diseases that were once largely controlled. For the U.S., this situation reinforces the need for robust public health surveillance and high vaccination rates to prevent the reintroduction and spread of such diseases.
What's Next?
Public health authorities in South Africa will continue to monitor the situation, implement contact tracing, and provide chemoprophylaxis to prevent further spread. Treatment protocols, including antibiotics like azithromycin or penicillin and diphtheria anti-toxin (DAT), will be administered to clear the organism and neutralize toxins. The dosage of DAT is determined by the duration and severity of the illness, with early administration being crucial for survival. Supportive care, including airway management, oxygen provision, and cardiac monitoring, will be provided as needed. The ongoing surveillance and response efforts aim to contain the outbreak and mitigate its impact. The situation may prompt a review of vaccination coverage and public health preparedness strategies in affected regions and potentially serve as a cautionary tale for other nations regarding the importance of maintaining high vaccination rates.
Beyond the Headlines
The resurgence of diphtheria in South Africa, a disease largely controlled in many parts of the world due to widespread vaccination, points to potential vulnerabilities in public health infrastructure or vaccine hesitancy. This situation could have broader implications for global health security, as it demonstrates how easily vaccine-preventable diseases can re-emerge if vaccination rates decline. It also underscores the importance of continuous public health education and access to healthcare, especially in regions facing multiple health challenges. The focus on early intervention and treatment highlights the ethical imperative to provide timely and effective medical care to prevent severe outcomes and fatalities from preventable diseases. This event could also lead to increased international collaboration on vaccine distribution and disease surveillance to prevent similar outbreaks globally.
